Dr. Olatoyosi M. Odenike
Claim this profileUniversity of Chicago Comprehensive Cancer Center
Studies T-Lymphoblastic Leukemia/Lymphoma
Studies Myeloid Leukemia
13 reported clinical trials
23 drugs studied
Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
TP53 positive
MLL positive
Stage IV
2Myeloid Leukemia
TP53 positive
MLL positive
Stage IV
Affiliated Hospitals
Clinical Trials Olatoyosi M. Odenike is currently running
Venetoclax + ASTX727
for Chronic Myelomonocytic Leukemia
This trial is testing if a combination of two drugs, ASTX727 and venetoclax, is more effective than ASTX727 alone in treating certain bone marrow cancers. It focuses on patients with CMML and MDS/MPN who have too many immature blood cells. ASTX727 helps produce normal blood cells and kills abnormal ones, while venetoclax blocks a protein that cancer cells need to survive. Venetoclax is an anticancer drug used to treat lymphomas and leukemias, but it has severe side effects.
Recruiting1 award Phase 2
Novel Therapies
for Acute Myeloid Leukemia
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid leukemia (AML): 1) daunorubicin and cytarabine liposome alone; 2) cytarabine and daunorubicin with venetoclax; 3) azacitidine and venetoclax; 4) daunorubicin and cytarabine liposome and venetoclax. "High-risk" refers to traits that have been known to make the AML harder to treat. Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Daunorubicin is in a class of medications called anthracyclines. It also works by slowing or stopping the growth of cancer cells in the body. Azacitidine is in a class of medications called demethylation agents. It works by helping the bone marrow to produce normal blood cells and by killing abnormal cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. There is evidence that these newer experimental treatment regimens may work better in getting rid of more AML compared to the standard approach of cytarabine and daunorubicin.
Recruiting1 award Phase 217 criteria
More about Olatoyosi M. Odenike
Clinical Trial Related20 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Olatoyosi M. Odenike has experience with
- Venetoclax
- Azacitidine
- Cytarabine
- Daunorubicin Hydrochloride
- Decitabine
- Selumetinib
Breakdown of trials Olatoyosi M. Odenike has run
T-Lymphoblastic Leukemia/Lymphoma
Myeloid Leukemia
Acute Myeloid Leukemia
Myelodysplastic Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Olatoyosi M. Odenike specialize in?
Olatoyosi M. Odenike focuses on T-Lymphoblastic Leukemia/Lymphoma and Myeloid Leukemia. In particular, much of their work with T-Lymphoblastic Leukemia/Lymphoma has involved TP53 positive patients, or patients who are MLL positive.
Is Olatoyosi M. Odenike currently recruiting for clinical trials?
Yes, Olatoyosi M. Odenike is currently recruiting for 5 clinical trials in Chicago Illinois. If you're interested in participating, you should apply.
Are there any treatments that Olatoyosi M. Odenike has studied deeply?
Yes, Olatoyosi M. Odenike has studied treatments such as Venetoclax, Azacitidine, Cytarabine.
What is the best way to schedule an appointment with Olatoyosi M. Odenike?
Apply for one of the trials that Olatoyosi M. Odenike is conducting.
What is the office address of Olatoyosi M. Odenike?
The office of Olatoyosi M. Odenike is located at: University of Chicago Comprehensive Cancer Center, Chicago, Illinois 60637 United States. This is the address for their practice at the University of Chicago Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.